The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the Pennsylvania state Prescription Drug Monitoring Program (PDMP).
The anacronym of the Pennsylvania PDMP is PA PDMP. It is administered by the Pennsylvania Department of Health. The email address is provided, along with the URLs of the main website and related websites for registering, query, data upload, statistics, opioid dashboard, training, and statute/regulation. Contact information is provided for the Director and the Senior Project Manager/Prescription Drug Monitoring Program. In 2020 the state population was 13,011,844, and there were 75,896 DEA-registered prescribers and 3,154 DEA-registered dispensers. There are seven transmitters of PDMP data. The substances monitored are those listed on Schedules II-V, medical marijuana dispensing, and naloxone/narcan administrations. Alternate data sources are fatal and non-fatal drug overdoses. Twenty types of reports are available from the PDMP, and it has 26 statistical capabilities. There are six engaged users of the PDMP, including in-state dispensers, Medicaid drug use in-state, and prescribers in and out of state. The budget for 2021 is $3,200,000. There are 31 PDMP employees. Funding sources are a BJA grant, the state general fund, and a CDC grant. Technologies used and integrations available are reported, along with interstate data-sharing partners. Significant dates in the creation and development of the PDMP are listed. Criteria for enrollment and accounts are reported. Training on enrollment and use is provided for the Attorney General, law enforcement personnel, and patients. Requirements are indicated for PDMP queries. Unsolicited reports/push notifications, and veterinary policies.
Similar Publications
- The Relationship between Police Contacts for Drug Use-related Crime and Future Arrests, Incarceration, and Overdoses: A Retrospective Observational Study Highlighting the Need to Break the Vicious Cycle
- Opioid Reduction Teleservices Program: Final Report to the Bureau of Justice Assistance Comprehensive Opioid, Stimulant, and Substance Abuse Program
- Prescription Drug Monitoring Program: Texas State Profile (2021)